Humabiologics, an industry leader in providing human-derived biomaterials for regenerative medicine, founded by scientists and tissue industry experts to address the gap between the gift of donated human tissues and researchers, and Fisher Scientific, a global leader in life sciences, are partnering to serve researchers in academia and industry who are working on regenerative medicine research.
Humabiologics develops and commercializes high-quality and affordable human-derived biomaterials for translational regenerative medicine applications such as cell therapy, bioprinting, tissue and disease modeling, or drug screening. Fisher Scientific, part of Thermo Fisher, is a fortune 100 global leader which has been serving the field of life sciences for more the 50 years.
“We are excited to partner with Fisher Scientific and expand our global network of reputable distributors around the world. Fisher Scientific is a well-known and respected life science company with quality products that are used in labs around the world every day.”
Humabiologics products have been used in several research applications including engineering human tissues, creating human tissue models for drug discovery and testing, modeling cancer environments, bioprinting, and many other applications. Several peer-reviewed publications have demonstrated the successful use of Humabiologics’ products to create clinically relevant human therapies and the possibility to create more relevant human tissue models to reduce or eliminate animal testing in the future.
Last year, Humabiologics introduced the world’s first native human collagen and gelatin bioinks. It also introduced the world’s first native human collagen and gelatin methacrylate for bioprinting applications. Humabiologics products are compatible with several commercially available bioprinters with excellent biocompatibility and printing performance compared to animal options. Humabiologics maintains an ISO 13485 certified quality system to facilitate the translation of innovative therapies from benchtop to clinic, quickly. Humabiologics continues to pave the way for future discoveries by developing organ- and tissue-specific human biomaterials.